CTX — Captor Therapeutics SA Income Statement
0.000.00%
Last trade - 00:00
- PLN370.73m
- PLN298.80m
- PLN13.20m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 3.99 | 9.16 | 13.2 |
Cost of Revenue | |||||
Gross Profit | 0 | 0 | 3.25 | 7.07 | 6.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.86 | 12.2 | 35.7 | 47.5 | 86.2 |
Operating Profit | -7.86 | -12.2 | -31.7 | -38.4 | -73 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.31 | -12.7 | -32.6 | -35.9 | -70.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.31 | -12.7 | -32.6 | -35.9 | -70.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.31 | -12.7 | -32.6 | -35.9 | -70.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.31 | -12.7 | -32.6 | -35.9 | -70.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.55 | -3.9 | -7.89 | -8.61 | -15.2 |
Dividends per Share |